Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Last trade$46.73
Day change-$0.89 (-1.87%)
Day range$43.37 – $48.05
Volume409,100
Market cap$3.50B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.5B
Price / earnings
—
Price / book
4×
Price / sales
—
EV / sales
—
EV / EBITDA
-24.78×
Profitability
Earnings per share
-$1.54
Return on assets
-12.65%
Return on equity
-12.94%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
45.95×
Quick ratio
45.95×
Cash ratio
7.79×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$66.41M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ELVN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$8.02M
$8.21M
$7.14M
$13.04M
$6.87M
$7.09M
$6.8M
$6.17M
Research and development
$28.02M
$29M
$20.69M
$21.25M
$18.23M
$21.49M
$24.9M
$20.72M
Total operating expenses
$36.05M
$37.21M
$27.82M
$34.29M
$25.1M
$28.58M
$31.69M
$26.9M
Operating income
-$36.05M
-$37.21M
-$27.82M
-$34.29M
-$25.1M
-$28.58M
-$31.69M
-$26.9M
Interest expense
$0
$4.73M
$4.2M
$0
$0
$3.25M
$3.2M
$0
Income before taxes
-$27.7M
-$32.49M
-$23.63M
-$29.67M
-$20.15M
-$25.34M
-$28.54M
-$23.18M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$27.7M
-$32.49M
-$23.63M
-$29.67M
-$20.15M
-$25.34M
-$28.54M
-$23.18M
Net income attributable to common shareholders
-$27.7M
-$32.49M
-$23.63M
-$29.67M
-$20.15M
-$25.34M
-$28.54M
-$23.18M
EBITDA
-$36.03M
-$37.2M
-$27.81M
-$34.24M
-$25.03M
-$28.5M
-$31.62M
-$26.82M
Basic earnings per share
-$0.36
-$0.49
-$0.38
-$0.48
-$0.32
-$0.49
-$0.57
-$0.46
Diluted earnings per share
-$0.36
-$0.49
-$0.38
-$0.48
-$0.32
-$0.49
-$0.57
-$0.46
Recent news
Company coverage with links to the original publishers.
The chronic myeloid leukemia (CML) clinical trial pipeline shows robust activity with 25+ pharmaceutical companies developing 25+ pipeline drugs. Key players including Merck, Enliven Therapeutics, ImmunoForge, and others are advancing promising therapies like TERN-701, ELVN-001, and KF1601 across various clinical stages. The market is evolving from established tyrosine kinase inhibitors toward newer selective agents targeting resistance, intolerance, and treatment-free remission.
OrbiMed Advisors sold 860,123 shares of Enliven Therapeutics (ELVN) for approximately $39 million on June 22, 2026, representing 11.60% of its holdings. Despite the partial exit following a 130% stock rally, OrbiMed retains over 6.5 million shares, signaling continued confidence. Enliven, a clinical-stage biotech focused on cancer therapies, has a strong cash position of $452.4 million and recently closed a $460 million public offering to fund operations through mid-2029.
OrbiMed Advisors, a major shareholder owning over 10% of Enliven Therapeutics, sold 281,408 shares for approximately $12.7 million on June 15, 2026. Despite the company's recent positive Phase III leukemia drug trial data and 95% one-year stock price gain, the insider sale raises questions about whether the hedge fund views the recent rally as a peak opportunity to take profits, though the sale could also reflect routine portfolio rebalancing.
Enliven Therapeutics' Chief Medical Officer Helen Collins sold 5,000 shares worth approximately $199,000 on May 18, 2026, as part of a pre-established Rule 10b5-1 trading plan. Despite the sale, Collins retains over 150,000 shares in the company, suggesting confidence in the biotech firm. The sale occurred during a period of strong stock performance, with the company up 135.2% over one year.
Clinical-stage biotech Enliven Therapeutics reported Q2 2025 results, highlighting positive Phase 1 clinical data for ELVN-001 in chronic myeloid leukemia and a strengthened cash position of $490.5 million following a $230 million public offering.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.